The new Erbitux data

On Sunday, Merck KGaA presented positive Phase II data for Erbitux cetuximab in colorectal cancer, providing a new benchmark for considering use of the antibody after ImClone's failed efforts to show efficacy in Phase II studies

Read the full 368 word article

How to gain access

Continue reading with a
two-week free trial.